XML 33 R20.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Schedule of Revenue by Payor Class Revenue by payor class as a percentage of total net service revenue is as follows:
For the Three-Month Periods Ended September 30,For the Nine-Month Periods
Ended September 30,
2021202020212020
Home Health:
     Medicare41 %41 %41 %41 %
     Non-Medicare - Episodic-based%%%%
     Non-Medicare - Non-episodic based12 %12 %12 %13 %
Hospice:
     Medicare34 %35 %34 %34 %
     Non-Medicare%%%%
Personal Care%%%%
100 %100 %100 %100 %
Schedule of Cash Cash Equivalents and Restricted Cash The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):
As of September 30, 2021As of December 31, 2020
Cash and cash equivalents$124.4 $81.8 
Restricted cash3.8 1.5 
Cash, cash equivalents and restricted cash$128.2 $83.3 
Schedule of Fair Value of Financial Instruments
The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):
 Fair Value at Reporting Date Using
Financial InstrumentCarrying Value as of September 30, 2021Quoted Prices in Active
Markets for Identical
Items
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant
Unobservable Inputs
(Level 3)
Long-term obligations$450.8 $— $468.5 $— 
Schedule of Weighted-Average Shares Outstanding The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):
 For the Three-
Month Periods
Ended September 30,
For the Nine-
Month Periods
Ended September 30,
 2021202020212020
Weighted average number of shares outstanding - basic32,607 32,662 32,658 32,469 
Effect of dilutive securities:
Stock options113 336 135 506 
Non-vested stock and stock units179 262 228 292 
Weighted average number of shares outstanding - diluted32,899 33,260 33,021 33,267 
Anti-dilutive securities141 36 82 31